8 results
8-K
EX-10.1
ADPT
Adaptive Biotechnologies Corp
12 Sep 22
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
8:45am
into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.
“Equity Interests” means
8-K
EX-10.2
wkdpzcj1k53gfgpusq
7 Aug 19
Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub
5:29pm
S-1
EX-10.18
6wso0f v3yri
30 May 19
IPO registration
5:20pm
DRS
EX-10.12
2q96vpd3obdoe70m9 d3
29 Mar 19
Draft registration statement
12:00am
- Prev
- 1
- Next